Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

NCT01484041 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Decision by company to cease development of dovitinib

Conditions

Breast Cancer

Interventions

DRUG: Dovitinib
DRUG: Aromatase Inhibitors

Sponsor

Georgetown University

Collaborators

[object Object]